Aktienanalyse zu Actinium Pharmaceuticals Inc (ATNM)ATNMActinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Actinium Pharmaceuticals Inc (ATNM) is a good buy right now due to its current price of $1.43, which is significantly below the analyst price target of $5.75, suggesting a potential upside of 342%. Additionally, the company reported a gross margin of 100% in Q2 2026, indicating strong profitability on its revenue. The main risk is the upcoming earnings date on November 13, 2026, where the estimated EPS is -0.25, which could lead to volatility if results do not meet expectations.

4 analysts cover ATNM: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 6.00.